Roche announced today that the European Commission (EC) has granted marketing authorisation for OCREVUS ® (ocrelizumab) for patients with active relapsing forms of multiple sclerosis defined by clinical or imaging features and for patients with early primary progressive multiple sclerosis in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory ac tivity. (Source: Roche Media News)

Read full article on